Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evommune, Inc. ( (EVMN) ) just unveiled an announcement.
Evommune, Inc. reported its fourth quarter and full-year 2025 results on March 5, 2026, highlighting positive Phase 2a proof-of-concept data for its injectable IL-18 binding protein fusion protein EVO301 in moderate-to-severe atopic dermatitis, with meaningful efficacy after two doses and a favorable safety profile. The company also advanced its first-in-class oral MRGPRX2 antagonist EVO756 with ongoing Phase 2b trials in chronic spontaneous urticaria and atopic dermatitis, expanded its cash position to a projected runway through 2028 via a $125 million private placement and collaboration revenue, and posted a 2025 net loss of $68.9 million as it increased R&D and G&A spending to support its growing clinical pipeline and indication expansion plans.
The most recent analyst rating on (EVMN) stock is a Buy with a $54.00 price target. To see the full list of analyst forecasts on Evommune, Inc. stock, see the EVMN Stock Forecast page.
Spark’s Take on EVMN Stock
According to Spark, TipRanks’ AI Analyst, EVMN is a Neutral.
The score is primarily held down by weak financial performance: widening losses, accelerating cash burn, and a highly leveraged balance sheet with negative equity. Technicals provide some offset with positive near-term momentum (price above DMA20 and positive MACD), but valuation cannot be meaningfully assessed due to missing P/E and dividend yield data.
To see Spark’s full report on EVMN stock, click here.
More about Evommune, Inc.
Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting key drivers of chronic inflammatory diseases such as atopic dermatitis and chronic spontaneous urticaria. The company aims to improve patients’ daily lives and prevent long-term effects of uncontrolled inflammation by advancing a differentiated pipeline of oral and injectable product candidates addressing unmet needs in immunology and inflammation.
Average Trading Volume: 621,676
Current Market Cap: $743.7M
Learn more about EVMN stock on TipRanks’ Stock Analysis page.